The first-generation biosynthetic cornea underwent many years of basic science and preclinical testing at academic institutions before beginning a clinical study in 2007 by investigators at the University of Linköping in Sweden. In 2014, the long-term results of this study were published in Biomaterials, a peer-reviewed scientific research journal.
The results garnered international attention, with the international science publication Nature calling the biosynthetic cornea “a resounding success.”
Ninety percent of cornea recipients were able to halt topical immunosuppressants after seven weeks. All of the patients in the clinical study were legally blind before the surgery, and achieved average best corrected vision of 20/54 after transplantation—which is good enough to drive in many parts of the world. Four of the 10 patients achieved best contact lens corrected vision of 20/25. There were no incidences of organ rejection, and the transplanted biosynthetic cornea was stable after four years of follow-up.
Click here to download the PDF article from Biomaterials Journal